Titan Pharmaceuticals (NASDAQ:TTNP) has been added to the broad U.S. market Russell 3000 index and the small-cap Russell 2000 index as part of Russell Investments’ annual reconstitution of its stock indexes, effective at the opening today.
“We are very pleased to be added to the Russell 3000 and 2000 indexes and we look forward to the broader exposure and potential interest in the company among new institutional investors that inclusion provides,” Titan CEO and president, Sunil Bhonsle, said in a statement.
“Titan’s inclusion in the Russell indexes comes on the heels of the recent approval by the FDA of Probuphine for the maintenance treatment of opioid addiction, and we hope to continue this momentum through the planned development of additional products based on our ProNeura long-term, continuous drug delivery platform,” he added.
